Don't want ads? Subscribe or login now.

Caribou Biosciences Brass Face Investor's Clinical Trials Suit

By Sydney Price · March 12, 2025, 7:53 PM EDT

Executives and directors of Caribou Biosciences Inc. have been hit with a shareholder's derivative suit alleging that they overstated the safety and efficacy of Caribou's cell therapy and concealed that the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Allen v. Braunstein et al

Case Number

3:25-cv-02463

Court

California Northern

Nature of Suit

Stockholders Suits

Date Filed

March 11, 2025

Recent Articles By Sydney

October 31, 2025
Obesity Drugmaker Escapes Clinical Trial Securities Suit
October 10, 2025
ATyr Pharma Faces Investor Suit Over Failed Drug Trial
October 10, 2025
Pharma Co. Escapes Suit Over Ex-CEO's Alleged Misconduct
October 07, 2025
Biogen Says Investors Can't Expand Alzheimer's Drug Suit
September 26, 2025
Semler Scientific, Bard To Pay $37M To End FCA Claims
September 24, 2025
UnitedHealth Fights Investor Suit Over DOJ's Merger Probe
September 23, 2025
Axsome Settles Investors' Drug Approval Suit For $7.8M
September 10, 2025
DexCom Beats Most Of Investors' Diabetes Device Sales Suit
August 25, 2025
Healthcare Co. Investors Sue Over Contractor's Alleged Fraud
August 22, 2025
Rite Aid Execs Dodge Investor Suit Over Opioid Litigation